Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostrate cancer (CPRC).

GC Buckle, L Werner, WK Oh, G Bubley… - Journal of Clinical …, 2010 - ascopubs.org
4660 Background: Treatments for CRPC are limited. CRPCs have activation of the PTEN-
PI3K-AKT pathway increasing mTOR expression which drives cell proliferation. We …
被引用次数：3 相关文章